CD4+ T-Cell Program Dynamics Under PD-1/PD-L1 Blockade in NSCLC
DOI:
https://doi.org/10.61173/3brnam90Keywords:
NSCLC, Immunotherapy, PD-1/PD-L1 blockade, CD4 T cells, BiomarkersAbstract
Immune checkpoint blockade (ICB) targeting PD-1/PDL1 has transformed non-small cell lung cancer (NSCLC) therapy, yet durable benefit remains limited to a subset of patients. While most mechanistic and biomarker frameworks emphasize CD8+ T cells, accumulating single-cell, TCR, and spatial evidence indicates that CD4+ T cells can act as system-level organizers of antitumor immunity and resistance. This paper synthesizes NSCLC studies from 2018-2025 and weighs conclusions using an evidence-tier framework that prioritizes intrapatient longitudinal sampling (paired tumor biopsies and/or serial blood) and spatially resolved profiling. Findings are integrated across five recurring CD4 programs: TLSassociated CXCL13+ Tfh-like states, Th1-oriented helper/effector states, Th17-linked inflammatory states, FOXP3+ regulatory T cells (Tregs), and proliferative/activation-toexhaustion trajectories. Across the strongest longitudinal tumor evidence, response most consistently aligns with coordinated on-therapy remodeling that strengthens TLS/Tfh organization and Th1-oriented output, whereas non-response is repeatedly linked to persistence or accumulation of activated intratumoral Treg states. Th17-associated signals show more variable directionality and remain lower-confidence under PD-1/PD-L1 blockade in NSCLC. Clonal tracking further connects benefit to productive proliferative bursts and blood-tumor clonal exchange within tumor-relevant T-cell pools. Together, these data support biomarker and treatment strategies that move beyond single markers toward composite, timeaware readouts capturing baseline immune infrastructure, suppressive balance, and on-therapy state transitions, and motivate rational combinations that relieve suppressive constraints while preserving productive CD4 help.
References
[1] Liu B, Hu X, Feng K, et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nature Cancer, 2022, 3(1): 108–121.
[2] Weng Y, Yuan J, Cui X, et al. The impact of tertiary lymphoid structures on tumor prognosis and the immune microenvironment in non-small cell lung cancer. Scientific Reports, 2024, 14(1): 16246.
[3] Ukita M, Hamanishi J, Yoshitomi H, et al. CXCL13- producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight, 2022, 7(12).
[4] Liu Z, Yang Z, Wu J, et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell, 2025, 188(11): 3081–3096.e19.
[5] Cui C, Wang J, Fagerberg E, et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes antitumor CD8 T cell responses. Cell, 2021, 184(25): 6101–6118. e13.
[6] Baxevanis C N, Sofopoulos M, Tsitsilonis O E, et al. Exploring the pivotal functions of tertiary lymphoid structures in cancer prognosis and immunotherapy outcomes. Cancers, 2025, 17(23): 3754.
[7] Brennan M, DeBruin D, Nwokolo C, et al. T-cell expression of CXCL13 is associated with immunotherapy response in a sex-dependent manner in patients with lung cancer. Cancer Immunology Research, 2024, 12(8): 956–963. Dean&Francis Yanxin Liang
[8] Zhang F, Bai H, Gao R, et al. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2020, 69(12): 2599–2611.
[9] Jiao S, Subudhi S K, Aparicio A, et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell, 2019, 179(5): 1177–1190.e13.
[10] Cao Q, Xue R, Zhang N. Th1 cells inducing IFNγ response improves immunotherapy efficacy in gastric cancer. Chinese Journal of Cancer Research, 2023, 35(3): 299–315.
[11] Wang J, Zhao X, Wan Y Y. Intricacies of TGF-β signaling in Treg and Th17 cell biology. Cellular & Molecular Immunology, 2023, 20(9): 1002–1022.
[12] Wu F, Fan J, He Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nature Communications, 2021, 12(1): 2540.
[13] Xing J, Man C, Liu Y, et al. Factors impacting the benefits and pathogenicity of Th17 cells in the tumor microenvironment. Frontiers in Immunology, 2023, 14: 1224269.
[14] Armstrong D, Chang C-Y, Lazarus D R, et al. Lung cancer heterogeneity in modulation of Th17/IL17A responses. Frontiers in Oncology, 2019, 9.
[15] Peng D H, Rodriguez B L, Diao L, et al. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nature Communications, 2021, 12(1): 2606.
[16] Anvar M T, Rashidan K, Arsam N, et al. Th17 cell function in cancers: Immunosuppressive agents or anti-tumor allies? Cancer Cell International, 2024, 24: 355.
[17] Nakazawa M, Charmsaz S, Hallab E, et al. Anti-CTLA4 therapy leads to early expansion of a peripheral Th17 population and induction of Th1 cytokines. Cancer Immunology Research, 2025, 13(6): 836–846.
[18] Wang R, Yang L, Zhang C, et al. Th17 cell-derived IL- 17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer. Oncoimmunology, 2018, 7(11): e1461303.
[19] Cho B C, Lee J S, Wu Y-L, et al. Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: A randomized, openlabel, phase 3 trial. Journal of Thoracic Oncology, 2023, 18(12): 1731–1742.
[20] Koh J, Hur J Y, Lee K Y, et al. Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Scientific Reports, 2020, 10(1): 18994.
[21] Kamada T, Togashi Y, Tay C, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proceedings of the National Academy of Sciences, 2019, 116(20): 9999–10008.
[22] van Gulijk M, van Krimpen A, Schetters S, et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Science Immunology, 2023, 8(83): eabn6173.
[23] Kim H, Kwon H J, Han Y B, et al. Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients. Modern Pathology, 2019, 32(3): 367–375.
[24] Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nature Immunology, 2020, 21(11): 1346–1358.
[25] Devi-Marulkar P, Fastenackels S, Karapentiantz P, et al. Regulatory T cells infiltrate the tumor-induced tertiary lymphoid structures and are associated with poor clinical outcome in NSCLC. Communications Biology, 2022, 5(1): 1416.
[26] Haruna M, Ueyama A, Yamamoto Y, et al. The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer. Scientific Reports, 2022, 12(1): 5377.
[27] Arnouk S M, Kancheva D, Van Damme H, et al. Depleting IL1R2+ tumor-infiltrating regulatory T cells with an ADCC- prone nanobody construct boosts the efficacy of anti-PD-1 immunotherapy. Cancer Research, 2025, 85(23): 4681–4700.
[28] Guo X, Zhang Y, Zheng L, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nature Medicine, 2018, 24(7): 978–985.
[29] Caushi J X, Zhang J, Ji Z, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature, 2021, 596(7870): 126–132.
[30] Pai J A, Hellmann M D, Sauter J L, et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumorspecific T cells during immune checkpoint blockade. Cancer Cell, 2023, 41(4): 776–790.e7.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
